Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective
Dequan Liu1, Lei Liu1, Xinghan Li2
1Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.
Abstract:
With the continuous advancements in tumor immunotherapy, researchers are actively exploring new treatment methods. Peptide therapeutic cancer vaccines have garnered significant attention for their potential in improving patient outcomes. Despite its potential, only a single peptide-based cancer vaccine has been approved by the U.S. Food and Drug Administration (FDA). A comprehensive understanding of the underlying mechanisms and current development status is crucial for advancing these vaccines. This review provides an in-depth analysis of the production principles and therapeutic mechanisms of peptide-based cancer vaccines, highlights the commonly used peptide-based cancer vaccines, and examines the synergistic effects of combining these vaccines with immunotherapy, targeted therapy, radiotherapy, and chemotherapy. While some studies have yielded suboptimal results, the potential of combination therapies remains substantial. Additionally, we addressed the management and adverse events associated with peptide-based cancer vaccines, noting their relatively higher safety profile compared to traditional radiotherapy and chemotherapy. Lastly, we also discussed the roles of adjuvants and targeted delivery systems in enhancing vaccine efficacy. In conclusion, this review comprehensively outlines the current landscape of peptide-based cancer vaccination and underscores its potential as a pivotal immunotherapy approach.
Insights
Peptide cancer vaccines show promise for improving immunotherapy outcomes. Combination therapies and advanced delivery systems are key to maximizing their potential and safety in cancer treatment.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Tumor immunotherapy is rapidly advancing, with peptide therapeutic cancer vaccines emerging as a significant area of research.
- Despite promising potential, only one peptide-based cancer vaccine is FDA-approved, highlighting the need for further development and understanding.
Purpose of the Study:
- To provide an in-depth review of peptide-based cancer vaccines.
- To analyze production principles, therapeutic mechanisms, and clinical development status.
- To explore combination strategies and future directions for enhancing vaccine efficacy.
Main Methods:
- Comprehensive literature review of peptide-based cancer vaccines.
- Analysis of production principles and therapeutic mechanisms.
- Examination of combination therapies (immunotherapy, targeted therapy, radiotherapy, chemotherapy) and adjuvant/delivery system roles.
Main Results:
- Peptide cancer vaccines offer a relatively high safety profile compared to traditional treatments.
- Combination therapies, while yielding some suboptimal results, show substantial potential for improved patient outcomes.
- Adjuvants and targeted delivery systems are crucial for enhancing vaccine efficacy.
Conclusions:
- Peptide-based cancer vaccination is a pivotal immunotherapy approach with significant potential.
- Further research into mechanisms, combination therapies, and delivery systems is essential for clinical advancement.
- Optimizing peptide vaccines offers a promising avenue for improving cancer treatment strategies.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...